MERS - A cautionary tale

Microbes and Infection

Volumn 17, Issue 8, 2015, Pages 542-544

  Häfner, Sophia ^a   Ojcius, David M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Microbes and Infection   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

CORONAVIRUS INFECTION; EBOLA HEMORRHAGIC FEVER; EDITORIAL; EPIDEMIC; FATALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MULTIPLE ORGAN FAILURE; PANDEMIC; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEVERE ACUTE RESPIRATORY SYNDROME; CLUSTER ANALYSIS;

CLUSTER ANALYSIS; CORONAVIRUS INFECTIONS; HUMANS;

EID: 84942825260     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2015.06.004     Document Type: Editorial

References (22)

1. Kobler S, Mahmound A, Lemon S, Mack A, Sivitz L, Oberholtzer K. In: Learning from SARS: preparing for the next disease outbreak-workshop summary. Washington, D.C: The National Academies Press; 2004.
2. Häfner S. Birds of ill omen-is H7N9 the harbinger of the next pandemic? Microbes Infect 2013;15:429-31.
3. Lu L, He B, Jiang S. The outbreak of avian influenza A (H7N9) in China: current status and future prospects. Biomed J 2013;36:96-7.
4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
5. Reusken CB, Haagmans BL, Muller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013;13:859-66.
6. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013;15:625-9.
7. Hotez PJ, Bottazzi ME, Tseng CT, Zhan B, Lustigman S, Du L, et al. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 2014;16:529-31.
8. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500:227-31.
9. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993;365:113.
10. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004;363:938-47.
11. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014;5:3067.
12. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 2014;111:4970-5.
13. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, et al. Protective effect of intranasal regimens containing peptidic MERS-CoV fusion inhibitor against MERS-CoV infection. J Infect Dis 2015. http://dx.doi.org/10.1093/infdis/jiV325 (first published online: June 8, 2015).
14. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, et al. Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J Virol 2014;88:7796-805.
15. Lu L, Xia S, Ying T, Jiang S. Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East Respiratory Syndrome (MERS). Emerg Microb Infect 2015;4:e37.
16. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-81.
17. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-15.
18. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-36.
19. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013;87:9939-42.
20. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, et al. A truncated receptorbinding domain of MERS-CoV spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013;8:e81587.
21. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2015. http://dx.doi.org/10.1038/cmi.2015.03. Advance online publication 2 February 2015.
22. Jiang S, Hotez PJ. Combating the emerging viral infectious diseases. Microbes Infect 2015;17:83.